2016
DOI: 10.1200/jco.2016.67.6601
|View full text |Cite|
|
Sign up to set email alerts
|

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Abstract: Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods Patients were randomly assigned at a ratio of one to one to receive chemotherapy with etoposide and platinum (cisplatin or carboplati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

9
359
0
7

Year Published

2017
2017
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 455 publications
(375 citation statements)
references
References 45 publications
9
359
0
7
Order By: Relevance
“…However, despite over 30 years of clinical trials designed to improve therapies for SCLC, the vast majority of SCLCs remain incurable. The median overall survival (mOS) for patients with metastatic SCLC receiving standard chemotherapy has remained in range of 9-11 months over the past 20+ years, even in the most recent large randomized clinical trials (2)(3)(4)(5)(6). While there is tremendous hope for therapeutic breakthroughs to come from improved preclinical models, promising new therapeutic strategies, and innovative clinical trials, it is instructive to review the current clinical management strategies for patients diagnosed with SCLC today.…”
Section: Introductionmentioning
confidence: 99%
“…However, despite over 30 years of clinical trials designed to improve therapies for SCLC, the vast majority of SCLCs remain incurable. The median overall survival (mOS) for patients with metastatic SCLC receiving standard chemotherapy has remained in range of 9-11 months over the past 20+ years, even in the most recent large randomized clinical trials (2)(3)(4)(5)(6). While there is tremendous hope for therapeutic breakthroughs to come from improved preclinical models, promising new therapeutic strategies, and innovative clinical trials, it is instructive to review the current clinical management strategies for patients diagnosed with SCLC today.…”
Section: Introductionmentioning
confidence: 99%
“…Ipilimumab (10 mg/ kg, q3w) byl srovnáván s placebem, hlavním cílem sledování bylo OS. Výsledky neprokázaly prodloužení PFS (4,6 vs. 4,4 měsíce, HR 0,85) ani OS (11,0 vs. 10,9 měsíce, HR 0,94; p = 0,3775) u pa cientů léčených kombinací s ipilimumabem [57]. V léčbě pa cientů s pokročilým stadiem NSCLC se úspěšně etablovaly zatím dva anti-PD-1 checkpoint inhibitory, nivolumab a pembrolizumab.…”
Section: Tremelimumabunclassified
“…Among 954 patients evaluable, median PFS and OS were 4.6 and 11 months in the chemotherapy plus ipilimumab arm and 4.4 and 10.9 in the control arm, respectively. These disappointing results have been worsened by the fact that, even if the rates and severity of adverse events have been similar in the two arms, the treatment-related discontinuation rate was higher in the experimental arm (18% vs. 2% in the control arm), with 5 treatment-related deaths in the chemotherapy plus ipilimumab arm and 2 in the chemotherapy plus placebo group (17).…”
mentioning
confidence: 91%